Bolt Biotherapeutics (BOLT) news

Recent news

First Tracks Biopharmaceuticals Inc. <TRAX.O>: Wells Fargo initiates coverage with overweight rating and target price $30

Wells Fargo Securities has initiated coverage of First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), assigning an "Overweight" rating and a target price of $30 per share. The firm highlighted the company’s focused immunology portfolio and its progress in advancing key drug candidates, including…

AInvest Wire · Jun 8, 2026

ImportantBolt Biotherapeutics: BDC-1001 continues to be well tolerated

AInvest Wire · Oct 23, 2023

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by